Athene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.01.23	Appendix 4C - Q2 FY23 Quarterly Cash Flow Report (PR Newswire)
09.01.23	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
06.01.23	Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) (PR Newswire)
03.01.23	Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (PR Newswire)
29.12.22	Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office (PR Newswire)
07.11.22	Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting (PR Newswire)
28.10.22	Appendix 4C - Q1 FY23 Quarterly Cash Flow Report (PR Newswire)
26.10.22	Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting (PR Newswire)
13.10.22	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
26.09.22	Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
20.09.22	Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy (PR Newswire)
25.08.22	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe (PR Newswire)
22.07.22	Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report (PR Newswire)
06.07.22	Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (PR Newswire)
27.06.22	Lockheed Martin Reduces Gross Pension Obligation by $4.3 Billion with Purchase of Group Annuity Contracts (PR Newswire)
23.06.22	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy (PR Newswire)
02.06.22	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy (PR Newswire)
27.04.22	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom (PR Newswire)
07.04.22	Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
07.03.22	Alterity Therapeutics to Present at the 34th Annual Roth Conference (PR Newswire)
28.01.22	Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease (PR Newswire)
27.01.22	Appendix 4C - Q2 FY22 Quarterly Cash Flow Report (PR Newswire)
06.01.22	Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's (PR Newswire)
05.01.22	Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire)
14.12.21	Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial (PR Newswire)
30.11.21	Athene Holding Ltd. Declares Fourth Quarter 2021 Preferred Stock Dividends (PR Newswire)
22.11.21	Alterity Therapeutics to Participate in Two Upcoming Investor Conferences (PR Newswire)
17.11.21	Alcoa Announces Transfer Of Approx. $1 Bln Of Pension Obligations - Quick Facts (RTTNews)
09.11.21	Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 (PR Newswire)
05.11.21	Athene Holding Ltd. Announces Date for Special General Meeting of Shareholders (PR Newswire)
05.11.21	Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases (PR Newswire)
04.11.21	Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases (PR Newswire)
29.10.21	Appendix 4C - Q1 FY22 Quarterly Cash Flow Report (PR Newswire)
28.10.21	Athene is the Lead Investor in the Combination of Wheels and Donlen (PR Newswire)
18.10.21	Newfi Announces Majority Sale to Athene from Warburg Pincus (PR Newswire)
20.09.21	Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 (PR Newswire)
31.08.21	Athene Holding Ltd. Declares Third Quarter 2021 Preferred Stock Dividends (PR Newswire)
05.08.21	Athene Holding Ltd. Reports Second Quarter 2021 Results (PR Newswire)
04.08.21	Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's (PR Newswire)
04.08.21	Lockheed Martin CFO Possenriede To Retire; Cuts FY EPS Outlook (RTTNews)
03.08.21	Athene Announces $4.9 Billion Pension Risk Transfer Transaction with Lockheed Martin (PR Newswire)
03.08.21	Lockheed Martin Reduces Gross Pension Obligation by $4.9 Billion with Purchase of Group Annuity Contracts (PR Newswire)
30.07.21	Appendix 4C - Q4 FY21 Quarterly Cash Flow Report (PR Newswire)
15.07.21	Athene to Acquire Foundation Home Loans (PR Newswire)
15.07.21	Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function (PR Newswire)
09.07.21	Athene Holding Ltd. to Announce Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021 (PR Newswire)
07.07.21	Athene Leads Minority Investment in Australia's Challenger Limited (PR Newswire)
01.07.21	Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's (PR Newswire)
11.06.21	Simon Property Chairman, President And CEO David Simon To Join Apollo Global Board - Quick Facts (RTTNews)
08.03.21	Apollo, Athene Holding, Decide To Merge- Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Alcon	77.70	1.92 %	K V
CieFinRichemont	122.45	1.07 %	K V
Lonza Grp	532.00	1.03 %	K V
Logitech Intl	72.32	0.17 %	K V
Zurich Insur Gr	552.00	0.00 %	K V
Swiss Life Hldg	718.40	-0.96 %	K V
Swisscom	503.50	-1.08 %	K V
ABB	49.42	-1.08 %	K V
Holcim	88.34	-1.60 %	K V
UBS Group	27.73	-2.19 %	K V

Nachrichten zu Athene Holding Ltd

Aktien Top/Flop

Meistgelesene Nachrichten